A Phase III Randomized, Double-Blind Trial of Chemoembolization With or Without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients With and Without Vascular Invasion.

Trial Profile

A Phase III Randomized, Double-Blind Trial of Chemoembolization With or Without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients With and Without Vascular Invasion.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 25 Jul 2018

At a glance

  • Drugs Sorafenib (Primary) ; Cisplatin; Doxorubicin; Mitomycin
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Jul 2018 Planned primary completion date changed from 1 Jul 2018 to 31 Dec 2018.
    • 02 Feb 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Jul 2018.
    • 07 Feb 2013 New source identified and integrated (Mayo Clinic record: 10-004516).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top